Obesity Clinical Trials in Los Angeles, California

17 studies are recruiting for obesity in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Los Angeles, California

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-1 Clinical Site, Los Angeles, California

   Locations

   122 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743463 on ClinicalTrials.gov

3. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

   The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Los Angeles Institute for Metabolic Research, Los Angeles, California

   Locations

   62 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07770841 on ClinicalTrials.gov

4. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Inglewood Clinical, Los Angeles, California

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

5. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

   The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may inclu…

   Stage

   Phase 3

   Ages

   12 to 17

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   69 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06439277 on ClinicalTrials.gov

6. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Childrens Hospital of Los Angeles, Los Angeles, California

   Locations

   117 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

7. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

   This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

   Stage

   Phase 2

   Ages

   7 to 25

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   16 in total

   Run by

   Etan Orgel

   See if you can join NCT05082519 on ClinicalTrials.gov

8. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   VAGrtrLosAngelesHlthcareSystem, Los Angeles, California

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

9. A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

   This early phase I trial studies how well a behavioral weight loss intervention consisting of a smartphone application and coaching works for the promotion of weight loss in adolescents and young adults after a stem cell transplant. This study may help researchers learn more about how adolescents a…

   Stage

   Not phased

   Ages

   13 to 30

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT04453072 on ClinicalTrials.gov

10. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment ar…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Vanda Investigational Site, Los Angeles, California

    Locations

    10 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT07446439 on ClinicalTrials.gov

11. Probiotic Intervention Study

    The current standard of care for obesity is the optimal management of comorbid conditions such as diabetes and hyperlipidemia, and counseling on diet, weight loss, or increased physical activity programs. However, lifestyle, diet, and behavioral interventions may provide between 7-10% reduction in …

    Stage

    Not phased

    Ages

    18 to 50

    Site

    University of California, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT06030362 on ClinicalTrials.gov

12. Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

    All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms:…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cedars Sinai Medical Center, Los Angeles, California

    Run by

    Cedars-Sinai Medical Center

    See if you can join NCT05653258 on ClinicalTrials.gov

13. Avoid and Resist Strategies for Weight Management

    The proposed randomized controlled trial tests two self-regulatory approaches to improve intentional weight loss and diet quality in individuals with overweight or obesity: (1) an environmental control strategy (AVOID) and (2) an impulse control training strategy (RESIST).

    Stage

    Not phased

    Ages

    14 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Run by

    Cedars-Sinai Medical Center

    See if you can join NCT05143931 on ClinicalTrials.gov

14. FEAST Perinatal Support Program Intervention

    Latino individuals face an elevated risk of adverse health outcomes during pregnancy, impacting both the birthing parent and the baby with potential long-term chronic health conditions. While promoting a healthy diet during pregnancy is a promising strategy, interventions targeting dietary behavior…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Run by

    University of Southern California

    See if you can join NCT06715787 on ClinicalTrials.gov

15. Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients

    Pilot study enrolling obese post HSCT (hematopoietic stem cell transplantation) patients at the hematology/oncology clinic at the Mattel Children's Hospital, University of California, Los Angeles. Parameters include percent over the 95th percentile (%BMIp95), zBMI, fasting metabolic metrics, addict…

    Stage

    Not phased

    Ages

    13 to 30

    Site

    UCLA Mattel Children's Hospital, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT04997473 on ClinicalTrials.gov

16. Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients

    evaluation of the EndoZip system procedure compared to the Apollo ESG procedure in obese patients.

    Stage

    Not phased

    Ages

    21 to 65

    Site

    Cedars Sinai Medical Center, Los Angeles, California

    Locations

    2 in total

    Run by

    Nitinotes Surgical Ltd.

    See if you can join NCT07090005 on ClinicalTrials.gov

17. Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

    Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sens…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UCLA Health, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT05419726 on ClinicalTrials.gov